MTOR and endometriosis: During endometriosis development, the mTOR/PI3K inhibitor GSK2126458 (75 μg in 100 μL/mouse/day) and RNA polymerase-I inhibitors, CX5461 and BMH-21 (1.25 mg in 100 μL/mouse/day), were administered orally five days per week for three weeks (Figure 1a).